- Home
- AER vs BIIB Comparison
AER vs BIIB Comparison
Compare AER & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AER
- BIIB
- Stock Information
- Founded
- AER 1995
- BIIB 1978
- Country
- AER Ireland
- BIIB United States
- Employees
- AER N/A
- BIIB N/A
- Industry
- AER Diversified Commercial Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- AER Consumer Discretionary
- BIIB Health Care
- Exchange
- AER Nasdaq
- BIIB Nasdaq
- Market Cap
- AER 17.7B
- BIIB 18.8B
- IPO Year
- AER 2006
- BIIB 1991
- Fundamental
- Price
- AER $115.19
- BIIB $133.23
- Analyst Decision
- AER Strong Buy
- BIIB Buy
- Analyst Count
- AER 8
- BIIB 27
- Target Price
- AER $119.25
- BIIB $188.17
- AVG Volume (30 Days)
- AER 1.1M
- BIIB 1.3M
- Earning Date
- AER 07-31-2025
- BIIB 07-31-2025
- Dividend Yield
- AER 0.92%
- BIIB N/A
- EPS Growth
- AER N/A
- BIIB 26.39
- EPS
- AER 11.21
- BIIB 10.12
- Revenue
- AER $8,055,588,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- AER $3.26
- BIIB N/A
- Revenue Next Year
- AER $1.97
- BIIB N/A
- P/E Ratio
- AER $10.46
- BIIB $12.41
- Revenue Growth
- AER 4.17
- BIIB 1.59
- 52 Week Low
- AER $82.21
- BIIB $110.04
- 52 Week High
- AER $118.07
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- AER 60.14
- BIIB 44.72
- Support Level
- AER $114.55
- BIIB $123.90
- Resistance Level
- AER $116.50
- BIIB $129.27
- Average True Range (ATR)
- AER 1.45
- BIIB 2.85
- MACD
- AER -0.22
- BIIB -0.66
- Stochastic Oscillator
- AER 73.58
- BIIB 19.77
About AER AerCap Holdings N.V.
AerCap Holdings NV is an aircraft leasing company. Its major activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties. Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include China, United States, and Other countries.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.